
Magdalena J Å**å**usarz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6898617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors—molecular dynamics study of the activated receptor–vasopressin–Gα systems. Journal of Peptide Science, 2006, 12, 180-189.	1.4	33
2	Molecular Docking-Based Study of Vasopressin Analogues Modified at Positions 2 and 3 withN-Methylphenylalanine:Â Influence on Receptor-Bound Conformations and Interactions with Vasopressin and Oxytocin Receptors. Journal of Medicinal Chemistry, 2006, 49, 2463-2469.	6.4	31
3	Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin—modeling of an activated state. Journal of Peptide Science, 2006, 12, 171-179.	1.4	27
4	Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: Molecular dynamics simulation of the agonist-bound state in the membrane–aqueous system. Biopolymers, 2006, 81, 321-338.	2.4	24
5	Oxytocin-Gly-Lys-Arg: A Novel Cardiomyogenic Peptide. PLoS ONE, 2010, 5, e13643.	2.5	23
6	Modeling protein structures with the coarse-grained UNRES force field in the CASP14 experiment. Journal of Molecular Graphics and Modelling, 2021, 108, 108008.	2.4	17
7	Molecular Modeling of the Neurohypophyseal Receptor/Atosiban Complexes. Protein and Peptide Letters, 2003, 10, 295-302.	0.9	15
8	Conformational stability of the fullâ€atom hexameric model of the ClpB chaperone from <i>Escherichia coli</i> . Biopolymers, 2010, 93, 47-60.	2.4	14
9	Conformational studies of vasopressin analogues modified with N-methylphenylalanine enantiomers in dimethyl sulfoxide solution. Biopolymers, 2006, 82, 603-614.	2.4	10
10	Exploring the Ligand Recognition Properties of the Human Vasopressin <scp>V</scp> 1a Receptor Using <scp>QSAR</scp> and Molecular Modeling Studies. Chemical Biology and Drug Design, 2014, 83, 207-223.	3.2	10
11	Influence of bulky 3,3′-diphenylalanine enantiomers replacing position 2 of AVP analogues on their conformations: NMR and molecular modeling studies. European Journal of Medicinal Chemistry, 2010, 45, 4065-4073.	5.5	8
12	Structure determination of UL49.5 transmembrane protein from bovine herpesvirus 1 by NMR spectroscopy and molecular dynamics. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 926-938.	2.6	8
13	Investigation ofcis/trans ratios of peptide bonds in AVP analogues containingN-methylphenylalanine enantiomers. Journal of Peptide Science, 2006, 12, 13-24.	1.4	7
14	Interactions of vasopressin and oxytocin receptors with vasopressin analogues substituted in position 2 with 3,3′â€diphenylalanine – a molecular docking study. Journal of Peptide Science, 2013, 19, 118-126.	1.4	6
15	Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 711-722.	5.0	6
16	PTD4 Peptide Increases Neural Viability in an In Vitro Model of Acute Ischemic Stroke. International Journal of Molecular Sciences, 2021, 22, 6086.	4.1	5
17	Molecular Dynamics Study of the Internal Water Molecules in Vasopressin and Oxytocin Receptors. Protein and Peptide Letters, 2009, 16, 342-350.	0.9	4
18	Theoretical studies, synthesis, and biological activity of 1-[(4-methylphenyl)sulfonyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonitrile (C9) as a non-peptide antagonist of the arginine vasopressin V1a and V2 receptors. Medicinal Chemistry Research, 2014, 23, 1581-1590.	2.4	4

#	Article	IF	CITATIONS
19	Investigation of the Effects of Primary Structure Modifications within the RRE Motif on the Conformation of Synthetic Bovine Herpesvirus 1â€Encoded UL49.5 Protein Fragments. Chemistry and Biodiversity, 2021, 18, e2000883.	2.1	1
20	Molecular modeling study of the opioid receptor interactions with series of cyclic deltorphin analogues. Journal of Peptide Science, 2011, 17, 554-564.	1.4	0